NEW YORK – Illumina said Monday that it will acquire proteomics technology originally developed by SomaLogic, among other assets, from Standard BioTools for $350 million in cash. The deal also includes up to $75 million in near-term milestone cash payments and performance-based royalties.

纽约——Illumina周一表示，将以3.5亿美元现金从Standard BioTools收购最初由SomaLogic开发的蛋白质组学技术等资产。该交易还包括高达7500万美元的近期里程碑现金付款和基于业绩的特许权使用费。

Under the terms of the deal, Standard BioTools will receive the add-on payments for assay services and sales of certain next-generation sequencing library preparation kits and array kits in fiscal years 2025 and 2026. The firm will also receive a 2 percent royalty on net revenues for 10 years.

根据协议条款，Standard BioTools 将在2025和2026财年获得某些下一代测序文库制备试剂盒和芯片试剂盒的检测服务及销售附加付款。该公司还将在10年内获得净收入2%的特许权使用费。

Illumina will also obtain facilities in Boulder, Colorado, including a CLIA- and CAP-certified lab as well as office and managerial space. Approximately 250 employees are associated with SomaLogic's commercial, R&D, lab, and manufacturing operations.

Illumina 还将获得位于科罗拉多州博尔德的设施，包括一家获得 CLIA 和 CAP 认证的实验室，以及办公和管理空间。大约 250 名员工与 SomaLogic 的商业、研发、实验室和制造业务相关联。

Standard BioTools will retain certain single Somamer reagent commercialization rights.

标准生物工具公司将保留某些单一Somamer试剂的商业化权利。

'The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance our strategy in multiomics with our customers at the forefront,' Illumina CEO Jacob Thaysen said in a statement. 'Illumina and SomaLogic have partnered closely for more than three years, and this combination accelerates our ability to serve our customers and produce better outcomes for patients through advanced biomarker discovery and disease profiling.'.

Illumina首席执行官雅各布·泰森在一份声明中表示：“收购SomaLogic将增强Illumina在不断扩展的蛋白质组学市场的地位，并推动我们以客户为中心的多组学战略。Illumina和SomaLogic已经紧密合作了三年多，此次结合将加速我们为客户提供服务的能力，并通过先进的生物标志物发现和疾病分析为患者带来更好的结果。”

Earlier this year, Illumina launched an

今年早些时候，Illumina 推出了一个

early-access program

早期访问计划

for its Protein Prep assay, developed in

用于其蛋白质制备分析，开发于

partnership

伙伴关系

with SomaLogic and Standard BioTools, which analyzes approximately 9,500 human protein targets using next-generation sequencing as a readout. The assay leverages SomaLogic's DNA aptamer-based protein detection technology.

与SomaLogic和Standard BioTools合作，使用下一代测序作为读数，分析大约9500个蛋白质靶标。该检测方法利用了SomaLogic基于DNA适配体的蛋白质检测技术。

Standard BioTools, formerly known as

标准生物工具，前身为

Fluidigm

Fluidigm

, announced plans to merge with SomaLogic in October 2023 and closed the deal in January 2024, despite

，于2023年10月宣布计划与SomaLogic合并，并在2024年1月完成了交易，尽管

opposition

反对

from SomaLogic officials and investors. The deal valued SomaLogic at little more than its cash on hand at the time of announcement; as of Sept. 30, 2023, SomaLogic had

来自SomaLogic的官员和投资者。该交易对SomaLogic的估值仅略高于其宣布时手头的现金；截至2023年9月30日，SomaLogic拥有

$453.8 million in cash

4.538亿美元现金

, cash equivalents, and investments.

，现金等价物和投资。

Whether Illumina considered buying SomaLogic in 2023 isn't clear. 'The acquisition was a natural next step in our successful, multiyear partnership as we prepare for the global Illumina Protein Prep commercial product launch,' an Illumina spokesperson said in an email. 'This combination increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling in ways partnership alone could not achieve.'.

Illumina是否在2023年考虑收购SomaLogic尚不清楚。Illumina发言人在一封电子邮件中表示：“此次收购是我们多年来成功合作的自然下一步，因为我们正在为全球Illumina蛋白质制备商业产品的推出做准备。” “这种结合增强了我们服务客户的能力，并加速了我们的技术路线图，以实现仅靠合作关系无法达成的先进生物标志物发现和疾病分析。”

In a statement, Standard BioTools CEO Michael Egholm said the deal 'validates the Standard BioTools thesis to transform underappreciated, high-potential assets and reflects the value created through the team’s hard work and disciplined execution. Upon completion, we will have even more financial firepower to continue building through strategic M&A while maintaining a clear focus on profitability.' Standard BioTools will come out the other side of the deal with approximately $550 million in cash..

在一份声明中，Standard BioTools 首席执行官迈克尔·埃戈尔姆表示，这笔交易“验证了 Standard BioTools 将被低估的高潜力资产进行转型的理念，并反映了团队通过努力工作和严谨执行所创造的价值。完成交易后，我们将拥有更多的资金实力，继续通过战略性并购扩大业务，同时保持对盈利能力的清晰关注。” 交易完成后，Standard BioTools 将持有约 5.5 亿美元现金。

Goldman Sachs is serving as financial adviser to Illumina while Centerview Partners is serving as financial adviser to Standard BioTools. UBS Investment Bank is serving as financial adviser to the Special Committee of the Standard BioTools Board of Directors.

高盛公司担任Illumina的财务顾问，而Centerview Partners担任Standard BioTools的财务顾问。瑞银投资银行担任Standard BioTools董事会特别委员会的财务顾问。

Illumina and SomaLogic will operate separately until the acquisition is closed sometime in the first half of 2026. Whether Illumina will continue to operate SomaLogic's clinical lab is also unclear; Illumina has its own CLIA- and CAP-certified lab.

Illumina 和 SomaLogic 将在 2026 年上半年某个时候收购完成前独立运营。 Illumina 是否会继续运营 SomaLogic 的临床实验室也不清楚；Illumina 拥有自己的 CLIA 和 CAP 认证实验室。

In Monday morning trading on the Nasdaq, shares of Illumina were flat at $90.34 while shares of Standard BioTools jumped 30 percent to $1.36.

周一上午纳斯达克的交易中，Illumina 的股价持平于 90.34 美元，而 Standard BioTools 的股价上涨了 30%，达到 1.36 美元。

Illumina's Thaysen said the firm 'will remain an open, accessible, and enabling NGS platform. The company is committed to maintaining and supporting its existing proteomics partnerships as well as continuing to develop the sequencing ecosystem and supporting a wide variety of multiomics solutions.'

Illumina的Thaysen表示，公司“将继续保持开放、可访问和赋能的NGS平台。该公司承诺维护并支持其现有的蛋白质组学合作伙伴关系，同时继续开发测序生态系统，并支持各种多组学解决方案。”